Haas Jason
SEC CIK 1883821 · EDGAR
BoughtSold
Most active insiders at LGND, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Espinoza Octavio | CFO | — | $13.03M |
| 2 | Reardon Andrew | CLO, Sec | — | $8.77M |
| 3 | Haas Jason | Dir | — | $3.74M |
| 4 | LAMATTINA JOHN L | Dir | — | $2.44M |
| 5 | Gray Nancy Ryan | Dir | — | $1.35M |
| 6 | Aryeh Jason | Dir | — | $1.25M |
| 7 | KOZARICH JOHN W | Dir | — | $1.20M |
| 8 | Sabba Stephen L | Dir | — | $1.16M |
| 9 | Zimmermann Martine | Dir | — | $342.0K |
| 10 | Davis Todd C | CEO, Dir | — | — |
Transactions 10
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-14 17:04 | 2026-08-12 | LGND | LIGAND PHARMACEUTICALS INC | Haas Jason | Dir | M - OptEx | $51.56 | +6,138 | 11.1K | +123% | +$316.5K |
| D | 2026-08-14 17:04 | 2026-08-12 | LGND | LIGAND PHARMACEUTICALS INC | Haas Jason | Dir | S - Sale+OE | $292.81 | -7,138 | 3,981 | -64% | -$2.09M |
| DM | 2026-06-15 21:06 | 2026-06-12 | LGND | LIGAND PHARMACEUTICALS INC | Haas Jason | Dir | M - OptEx | $51.56 | +4,000 | 11.4K | +54% | +$206.2K |
| DM | 2026-06-15 21:06 | 2026-06-12 | LGND | LIGAND PHARMACEUTICALS INC | Haas Jason | Dir | S - Sale+OE | $255.58 | -6,461 | 4,981 | -56% | -$1.65M |
| D | 2026-06-09 19:35 | 2026-06-05 | LGND | LIGAND PHARMACEUTICALS INC | Haas Jason | Dir | A - Grant | $0.00 | +836 | 7,442 | +13% | $0 |
| 2026-05-11 20:32 | 2026-05-08 | ODTX | Odyssey Therapeutics, Inc. | Haas Jason | CFO | P - Purchase | $20.00 | +1,000 | 62.9K | +2% | +$20.0K | |
| D | 2025-06-10 | 2025-06-06 | LGND | LIGAND PHARMACEUTICALS INC | Haas Jason | Dir | A - Grant | $0.00 | +1,209 | 6,606 | +22% | $0 |
| D | 2024-06-18 | 2024-06-14 | LGND | LIGAND PHARMACEUTICALS INC | Haas Jason | Dir | A - Grant | $0.00 | +1,252 | 5,397 | +30% | $0 |
| D | 2023-06-13 | 2023-06-09 | LGND | LIGAND PHARMACEUTICALS INC | Haas Jason | Dir | A - Grant | $0.00 | +1,142 | 4,145 | +38% | $0 |
| D | 2022-06-30 | 2022-06-29 | LGND | LIGAND PHARMACEUTICALS INC | Haas Jason | Dir | A - Grant | $0.00 | +1,750 | 1,750 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations